 Vidarabine
"Vidarabine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
| Descriptor ID |
D014740
|
| MeSH Number(s) |
D03.438.759.590.138.900 D13.570.065.950 D13.570.583.138.900
|
| Concept/Terms |
Vidarabine- Vidarabine
- beta-Ara A
- A, beta-Ara
- beta Ara A
- Adenine Arabinoside
- Arabinoside, Adenine
- alpha-D-Arabinofuranosyladenine
- alpha D Arabinofuranosyladenine
- Ara A
- A, Ara
- alpha-Ara A
- A, alpha-Ara
- alpha Ara A
- Arabinofuranosyladenine
- Arabinosyladenine
- 9-beta-D-Arabinofuranosyladenine
- 9 beta D Arabinofuranosyladenine
- 9-beta-Arabinofuranosyladenine
- 9 beta Arabinofuranosyladenine
- Ara-A
Vira-A- Vira-A
- Vira A
- ViraA
- Parke Davis Brand of Vidarabine
- Monarch Brand of Vidarabine
|
Below are MeSH descriptors whose meaning is more general than "Vidarabine".
Below are MeSH descriptors whose meaning is more specific than "Vidarabine".
This graph shows the total number of publications written about "Vidarabine" by people in UAMS Profiles by year, and whether "Vidarabine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2023 | 0 | 1 | 1 | | 2018 | 1 | 0 | 1 | | 2015 | 0 | 1 | 1 | | 2014 | 0 | 1 | 1 | | 2011 | 0 | 1 | 1 | | 2005 | 1 | 0 | 1 | | 2004 | 1 | 0 | 1 | | 1998 | 1 | 0 | 1 | | 1992 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Vidarabine" by people in Profiles over the past ten years.
-
Alkhaldi H, Goloubeva O, Rapoport AP, Dahiya S, Pang Y, Ali MM, Hardy NM, Mohindra P, Bukhari A, Lutfi F, Sanchez-Petitto G, Molitoris J, Samanta S, Li X, Toth T, Landau M, Hodges S, Nishioka J, Ruehle K, Ridge L, Gahres N, Kocoglu MH, Atanackovic D, Malinou JN, Yared JA. Outcomes of Busulfan, Fludarabine, and 400 cGy Total Body Irradiation Compared With Busulfan and Fludarabine Reduced-Intensity Conditioning Regimens for Allogeneic Stem Cell Transplantation in Adult Patients With Hematologic Diseases: A Single-Center Experience. Transplant Proc. 2023 Jan-Feb; 55(1):214-224.
-
Jain T, Alahdab F, Firwana B, Sonbol MB, Almader-Douglas D, Palmer J. Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis. Biol Blood Marrow Transplant. 2019 04; 25(4):728-733.
-
Li Z, Li F, Yi S, Gu Z, Yu Z, Xu Y, Feng X, Liu W, Zou D, Qi J, Zhan F, Qiu L. Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China. BMC Cancer. 2015 Jul 29; 15:555.
|
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|